1. Home
  2. ADUS vs IBRX Comparison

ADUS vs IBRX Comparison

Compare ADUS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADUS
  • IBRX
  • Stock Information
  • Founded
  • ADUS 1979
  • IBRX 2014
  • Country
  • ADUS United States
  • IBRX United States
  • Employees
  • ADUS N/A
  • IBRX N/A
  • Industry
  • ADUS Medical/Nursing Services
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ADUS Health Care
  • IBRX Health Care
  • Exchange
  • ADUS Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • ADUS 2.2B
  • IBRX 2.4B
  • IPO Year
  • ADUS 2009
  • IBRX N/A
  • Fundamental
  • Price
  • ADUS $131.40
  • IBRX $2.62
  • Analyst Decision
  • ADUS Buy
  • IBRX Buy
  • Analyst Count
  • ADUS 10
  • IBRX 2
  • Target Price
  • ADUS $133.67
  • IBRX $17.38
  • AVG Volume (30 Days)
  • ADUS 171.7K
  • IBRX 6.1M
  • Earning Date
  • ADUS 11-04-2024
  • IBRX 11-12-2024
  • Dividend Yield
  • ADUS N/A
  • IBRX N/A
  • EPS Growth
  • ADUS 23.71
  • IBRX N/A
  • EPS
  • ADUS 4.37
  • IBRX N/A
  • Revenue
  • ADUS $1,133,806,000.00
  • IBRX $7,332,000.00
  • Revenue This Year
  • ADUS $10.05
  • IBRX $2,572.99
  • Revenue Next Year
  • ADUS $22.66
  • IBRX $747.59
  • P/E Ratio
  • ADUS $30.10
  • IBRX N/A
  • Revenue Growth
  • ADUS 10.15
  • IBRX 1218.71
  • 52 Week Low
  • ADUS $85.94
  • IBRX $2.61
  • 52 Week High
  • ADUS $136.12
  • IBRX $10.53
  • Technical
  • Relative Strength Index (RSI)
  • ADUS 63.37
  • IBRX 28.04
  • Support Level
  • ADUS $126.08
  • IBRX $2.61
  • Resistance Level
  • ADUS $131.93
  • IBRX $3.18
  • Average True Range (ATR)
  • ADUS 3.46
  • IBRX 0.28
  • MACD
  • ADUS 1.23
  • IBRX -0.20
  • Stochastic Oscillator
  • ADUS 92.04
  • IBRX 0.40

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Share on Social Networks: